Functional ablation of CHK1 via siRNA markedly inhibited proliferation and enhanced radiosensitivity in both TP53 wild-type (AGS) and TP53-mutant (MKN1) gastric cancer cell lines, indicating that CHK1-driven tumor growth and therapeutic resistance may be independent of TP53 status. Here, TP53 is linked to gastric cancer.